Destructive Mono-Arthritis Caused by Mycobacterium bovis during Treatment with Pembrolizumab in a Patient Previously Treated with BCG Instillations for Bladder Cancer: A Case Report

E. Cynthia, Huijts Susanne M, Lubbe Peter AHM van der, Robbrecht Debbie G.J.
{"title":"Destructive Mono-Arthritis Caused by Mycobacterium bovis during Treatment with Pembrolizumab in a Patient Previously Treated with BCG Instillations for Bladder Cancer: A Case Report","authors":"E. Cynthia, Huijts Susanne M, Lubbe Peter AHM van der, Robbrecht Debbie G.J.","doi":"10.23937/2643-4563/1710026","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitor (ICI) treatment is an integral part of second line treatment of patients with urothelial carcinoma (UC) as well as in first line in cisplatin-ineligible patients with PD-L1 positive tumours. A substantial proportion of patients with bladder cancer have been treated with intravesical Mycobacterium bovis BCG in the past. Although it is rare, disseminated infections with Mycobacterium bovis have been described, but not in association with ICI treatment. We herein report a case of destructive monoarthritis caused by Mycobacterium bovis in a patient previously treated with intravesical BCG and a recent initiation of the ICI pembrolizumab in first line for metastatic UC. A culture of synovial fluid from the involved wrist was positive for Mycobacterium bovis. Based on whole genome sequencing based-subtyping, the identified Mycobacterium was shown to be related with the previous BCG instillations. Because of severe complaints and progressive destruction of the patients’ wrist, it was decided to interrupt the pembrolizumab. At that moment, following the seventh cycle of pembrolizumab, evaluation showed a partial disease response. Following systemic treatment with triple combination therapy (Isoniazid, Rifampicin, Ethambutol) and surgery, the complaints of the wrist gradually improved. This is the first report describing a disseminated Mycobacterium bovis infection in a patient treated with an ICI and previous BCG instillations for bladder cancer. This is of relevance, because an increasing number of bladder cancer patients, previously treated with BCG instillations, will be treated with an ICI in advanced disease setting.","PeriodicalId":93572,"journal":{"name":"International journal of oncology research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2643-4563/1710026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Immune checkpoint inhibitor (ICI) treatment is an integral part of second line treatment of patients with urothelial carcinoma (UC) as well as in first line in cisplatin-ineligible patients with PD-L1 positive tumours. A substantial proportion of patients with bladder cancer have been treated with intravesical Mycobacterium bovis BCG in the past. Although it is rare, disseminated infections with Mycobacterium bovis have been described, but not in association with ICI treatment. We herein report a case of destructive monoarthritis caused by Mycobacterium bovis in a patient previously treated with intravesical BCG and a recent initiation of the ICI pembrolizumab in first line for metastatic UC. A culture of synovial fluid from the involved wrist was positive for Mycobacterium bovis. Based on whole genome sequencing based-subtyping, the identified Mycobacterium was shown to be related with the previous BCG instillations. Because of severe complaints and progressive destruction of the patients’ wrist, it was decided to interrupt the pembrolizumab. At that moment, following the seventh cycle of pembrolizumab, evaluation showed a partial disease response. Following systemic treatment with triple combination therapy (Isoniazid, Rifampicin, Ethambutol) and surgery, the complaints of the wrist gradually improved. This is the first report describing a disseminated Mycobacterium bovis infection in a patient treated with an ICI and previous BCG instillations for bladder cancer. This is of relevance, because an increasing number of bladder cancer patients, previously treated with BCG instillations, will be treated with an ICI in advanced disease setting.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一例先前接受BCG灌注治疗膀胱癌症的患者在接受Pembrolizumab治疗期间由牛分枝杆菌引起的破坏性单关节炎:病例报告
免疫检查点抑制剂(ICI)治疗是尿路上皮癌(UC)患者二线治疗以及PD-L1阳性肿瘤顺铂不合格患者一线治疗的组成部分。相当一部分癌症患者过去曾接受过膀胱内牛分枝杆菌BCG治疗。虽然牛分枝杆菌的播散性感染很罕见,但与ICI治疗无关。我们在此报告了一例由牛分枝杆菌引起的破坏性单关节炎患者,该患者先前接受过膀胱内BCG治疗,最近开始在转移性UC的一线使用ICI pembrolizumab。来自受累手腕的滑膜液培养物对牛分枝杆菌呈阳性。基于全基因组测序的分型,鉴定出的分枝杆菌与以前的BCG滴注有关。由于严重的主诉和患者手腕的逐渐损伤,决定中断pembrolizumab治疗。在那一刻,pembrolizumab第七个周期后,评估显示部分疾病反应。经过三重联合治疗(异烟肼、利福平、乙胺丁醇)和手术的全身治疗,手腕的主诉逐渐改善。这是第一份报告,描述了一名接受ICI和先前BCG膀胱癌症滴注治疗的患者的牛分枝杆菌感染。这是相关的,因为越来越多的癌症患者,以前接受过BCG滴注治疗,将在晚期疾病环境中接受ICI治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Liver Metastasis: Current Concepts in Management and Future Perspectives RNA m6A Modifications and Cancer Dose Variation Profiles of Small Fields with a 10 MV Photon Beam Two Cases of Primary Leiomyosarcoma of the Vagina: Histomorphologic Presentation with Review of the Literature Borderline Ovarian Tumors a Five-year Retrospective Clinicopathologic Study of 69 Cases in Egyptian NCI (2013-17)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1